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ABSTRACT
Vitamin D deficiency is now recognized as a
condition of increasing prevalence worldwide.
Vitamin D has an established role in calcium
and bone metabolism; however, more recently
associations with vitamin D deficiency and risk
of developing diabetes, diabetes complications,
and cardiovascular disease have all been
acknowledged. The vitamin D receptor is
ubiquitously expressed, and experimental,
in vitro, and in vivo studies strongly suggest a
role in regulating the transcription of multiple
genes beyond calcium homeostasis. These
include antiproliferative, immunomodulatory,
angiogenic, inhibition of the
renin–angiotensin–aldosterone system, and
neurotrophic factor expression. Observational
studies report a strong association between
vitamin D deficiency and cardiovascular and
metabolic disorders; however, there remains a
paucity of large long-term randomized clinical
trials showing a benefit with treatment. An
increasing body of literature suggests a possible
pathogenetic role of vitamin D in the long-term
complications of diabetes and vitamin D
deficiency may also exacerbate symptoms of
painful diabetic peripheral neuropathy. It
remains unknown if supplementation of
vitamin D to normal or non-deficient levels
alters pathogenetic processes related to diabetic
microvascular complications. With the high
prevalence of vitamin D deficiency in patients
with diabetes and putative mechanisms linking
vitamin D deficiency to diabetic complications,
there is a compelling argument for undertaking
large well-designed randomized controlled trials
of vitamin D supplementation.
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INTRODUCTION
There is an epidemic of vitamin D deficiency,
with over one billion people worldwide affected
[1]. Our previously published UK data indicates
that vitamin D deficiency
(25-hydroxyvitamin D [25(OH)D] \30 ng/mL)
occurs in 91% of patients with diabetes, with
severe deficiency [25(OH)D\10 ng/mL] in 32%
of patients [2]. The purpose of this review was to
examine the association between vitamin D
status and cardiovascular disease, with
particular reference to diabetes mellitus and its
complications.
This review is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
VITAMIN D AND THE VITAMIN D
RECEPTOR
Vitamin D is a lipid-soluble, secosteroid
hormone which is primarily associated with
calcium homeostasis [3]. Synthesis of vitamin D
occurs predominantly in the skin from
dehydrocholesterol, the shared common
precursor with cholesterol, and is dependent
on sun exposure [4]. Ultraviolet B light of
wavelengths between 280 and 315 nm is
optimal for the conversion of
7-dehydrocholesterol to previtamin D3, which
is then converted to vitamin D3 in the skin.
During summer, exposure to midday sunlight
for 20–30 min, two or three times per week is
thought to be sufficient in generating adequate
levels of vitamin D for a fair-skinned individual
[5]. Table 1 outlines the significant risk factors
for vitamin D deficiency. The amount of
synthesized vitamin D is reduced in
darker-skinned, older, and obese individuals
[5]. Other sources of vitamin D include diet
(food that contains natural vitamin D or
fortified vitamin D) and dietary supplements
[3]. Dietary vitamin D usually contains vitamin
D3 (cholecalciferol) with few natural sources
containing vitamin D2 (ergocalciferol) [3].
Vitamin D from the skin and diet is modified
in the liver to generate 25(OH)D [3]. Active
vitamin D is formed when further conversion
takes place in the kidneys forming
1,25-dihydroxyvitamin D [1,25(OH)2D3
(activated vitamin D)] [3].
Vitamin D status is defined by measuring the
level of 25(OH)D in the blood owing to its
longer half-life in plasma, where it forms a
circulating reservoir of vitamin D [3]. A serum
concentration of [30 ng/mL ([75 nmol/L) is
considered as sufficient, 20–30 ng/mL
(50–75 nmol/L) as insufficient, 10–20 ng/mL
(25–50 nmol/L) as deficient, and \10 ng/mL
(\25 nmol/l) as severely deficient [3]. The US
Institute of Medicine (IoM) released guidance in
2011 in which 25(OH)D equal to 20 ng/mL was
considered to be adequate for C97.5% of the
population [6]; however, this has been heavily
criticized by the Endocrine Society [7, 8] and
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they recommend that 25(OH)D concentration
should exceed 30 ng/mL, to maximize the effect
of vitamin D on calcium, bone, and muscle
metabolism. Cutoffs for vitamin D status are
detailed in Table 2. Both the IoM and the
Endocrine Society have arbitrated respective
cutoffs for optimal vitamin D status; however,
these are based on bone metabolic data and not
on cardiometabolic data [9]. Optimal levels of
25(OH)D for possible prevention of
cardiometabolic outcomes remain to be
elucidated [10].
Vitamin D insufficiency which is not low
enough to cause bone disease is significantly
associated with cardiovascular disease [11].
There is a ubiquitous expression of vitamin D
receptors (VDR) in virtually every human tissue,
and vitamin D is an important regulator of
literally hundreds of genes regulating key
biological processes from cell division to
apoptosis [11].
VDR is widely distributed in many tissues
[12], which suggests a putative biological
response with its activation, implying that
VDR has multiple functions beyond calcium
homeostasis [12]. Once 1,25(OH)2D3 binds to
VDR, it interacts with the retinoid X receptor
(RXR) forming a heterodimer that binds to
vitamin D responsive elements in the region
of genes directly controlled by 1,25(OH)2D3
[13]. The action of vitamin D in a particular cell
depends on the vitamin D-mediated gene
activation, transcriptional response, and
protein formation [13]. For example, in
addition to stimulating intestinal calcium and
phosphate absorption to effect skeletal and
mineral ion homeostasis, 1,25(OH)2D3/
VDR-RXR also regulates the expression of a
plethora of genes in non-calcemic tissues [12].
This extensive vitamin ‘‘D-ome’’ allows the
concerted genomic and rapid actions of
1,25(OH)2D3 to possibly have an interplay
with such varied diseases as osteoporosis,
cancer, diabetes, atherosclerosis, vascular
disease/calcification, and infection [12].
Furthermore, the VDR gene is expressed
within developing neurons of rodent dorsal
root ganglia, which may suggest a role for
vitamin D in peripheral nervous system
development and nociception [14].
VITAMIN D
AND CARDIOVASCULAR DISEASE
The Framingham Offspring Study assessed
subjects with no prior diagnosis of
cardiovascular disease. Subjects with severe
vitamin D deficiency (25(OH)D \10 ng/mL)
experienced a hazard ratio of 1.80 [95%
confidence interval (CI), 1.05–3.08] for
developing a first cardiovascular event 5 years
after follow-up compared with subjects with
higher levels of 25(OH)D ([15 ng/mL) [15]. In
the Health Professionals Follow-Up Study, men
without prior cardiovascular disease and
vitamin D levels of \15 ng/mL showed a
twofold increase in the rate of myocardial
infarction [16]. A cross-sectional study by
Dobnig et al. [17] found an inverse
relationship between lower levels of vitamin D
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and increased risk of all-cause and
cardiovascular mortality. Other cross-sectional
observational studies have confirmed that lower
vitamin D levels are associated with endothelial
dysfunction as well as arterial stiffness [18]. The
vasoprotective action of vitamin D may be
mediated by increasing nitric oxide (NO)
production, inhibiting foam cell formation,
and reducing the expression of adhesion
molecules in endothelial cells [19–21]. The
recognition of specific VDR genetic
susceptibility in the pathophysiology of
hypertension has further supported these
insights [22]. With regards to cerebrovascular
disease, in a large population-based prospective
study in Copenhagen, an increase risk of
symptomatic ischemic stroke was observed
with decreasing plasma 25(OH)D
concentrations [23]. A similar association with
vitamin D deficiency was also demonstrated in
the Honolulu Heart Program, which studied
7385 men over a 34-year period [24]. In a study
of 250 stroke patients in India, a deficiency of
25(OH)D was independently associated with
ischemic stroke, especially large artery
atherosclerosis and cardioembolic stroke [25].
Studies are needed to establish if vitamin D
supplementation reduces the risk of ischemic
stroke in the general population.
Li et al. established that VDR knockout mice
have elevated blood pressure, cardiac
hypertrophy, and elevated activation of the
renin–angiotensin–aldosterone system (RAAS),
which can be reversed with an
angiotensin-converting enzyme (ACE)
inhibitor [26, 27]. RAAS plays a pivotal role in
maintaining sodium and blood volume
homeostasis by modulating renal function and
blood pressure [28]. Upregulation of RAAS leads
to the development of hypertension and
increased cardiovascular risk [28]. RAAS
induces recruitment and activation of
inflammatory cells within the vessel wall,
promoting endothelial dysfunction and
increasing vascular permeability [28]. This
inflammatory response stimulates hyperplasia
and hypertrophy of vascular smooth muscle
cells and the release of pro-inflammatory
molecules (VCAM-1, monocyte
chemoattractant protein-1, interleukins 6 and
8) [28]. Li et al. also showed that wild-type mice
given an injection of 1,25(OH)2D3
demonstrated suppression of renin mRNA
expression [26, 27]. Vitamin D is a potent
negative regulator of the RAAS system, which
may play an important role in the development
of neuropathy in diabetes. RAAS inhibition is
one of the few proven therapies, which may
prevent or delay diabetic peripheral neuropathy
(DPN), evidenced by experimental studies but
also two human clinical trials [29–31]. In an
experimental model of type 1 diabetes mellitus,
plasma renin activity levels were decreased
whereas ACE activity was increased in diabetic
rats compared with controls [31]. A small
open-label study of lisinopril in hypertensive
subjects (n = 13) showed improvements in
nerve conduction measures over 12 weeks [29]
and a double-blind randomized controlled
study found that administration of the ACE
inhibitor trandolapril in normotensive patients
with mild diabetic neuropathy resulted in an
improvement in neurophysiology over
12 months [30].
In a randomized controlled trial (RCT) by
Trivedi et al. [32], vitamin D3 100,000 IU was
supplemented every 4 months for 5 years versus
placebo to assess fracture risk. There was a
non-significant trend [risk ratio (RR), 0.84;
95% CI, 0.055–1.10] toward a reduction in
cardiovascular deaths. A further RCT (n = 302)
added vitamin D to ongoing calcium
supplementation with a primary endpoint of
the risk of falls [33]. They reported as adverse
14 Diabetes Ther (2016) 7:11–26
events ischemic heart disease event rates of
1.3% in those on vitamin D versus 2.0% for
placebo (only two versus three events). These
two RCTs were analyzed in a meta-analysis
which reported no significant benefit for
vitamin D supplementation [34]. In the
Women’s Health Initiative (WHI) study
(ClincialTrials.gov identifier, NCT00000611),
36,282 women were randomized to receive a
combination of vitamin D3 400 IU and calcium
1000 mg per day or placebo [35]. Myocardial
infarction or coronary heart disease death was
confirmed for 499 women assigned to calcium/
vitamin D and 475 women assigned to placebo
(hazard ratio, 1.04; 95% CI, 0.92–1.18) [35]. It
was concluded that calcium plus vitamin D
supplementation neither increased nor
decreased coronary or cerebrovascular risk in
generally healthy postmenopausal women over
a 7-year use period [36].
VITAMIN D AND DIABETES
VDR have also been identified in pancreatic
beta cells, and vitamin D deficiency has been
shown to impair insulin synthesis and secretion
in animal models of diabetes, suggesting a role
in the development of type 2 diabetes [37].
Vitamin D deficiency is known to increase the
levels of parathyroid hormone. This in turn has
been linked to increased insulin resistance,
which is associated with diabetes,
hypertension, inflammation, and increased
cardiovascular risk [38]. Several studies,
including one published by Scragg et al. [39],
demonstrated that lower vitamin D levels were
associated with an increased risk of diabetes
[28]. A double-blinded placebo trial by Mitri
et al. [40] showed that in adults at risk of type 2
diabetes, short-term supplementation with
cholecalciferol improved beta cell function
and had a marginal effect on attenuating the
rise in HbA1c. Furthermore, two studies have
shown an inverse relationship of 25(OH)D with
HbA1c in subjects with and without diabetes
[41, 42]. Devaraj et al. [43] found that the first
quartile of serum 25(OH)D level, compared
with the fourth quartile, was associated with
an increased adjusted odds ratio (OR) for
prediabetes and vitamin D levels were
inversely correlated with fasting glucose
(r = -0.29, P = 0.04) and homeostasis model
assessment (HOMA) (r = -0.34, P = 0.04).
However, in the WHI study, of 33,951
participants receiving calcium plus vitamin D3
supplementation, there was no reduction in the
risk of developing diabetes over 7 years [36].
Vitamin D also has an immunomodulatory
effect as suggested by a study of more than
10,000 Finnish children who were given
2000 IU vitamin D3 per day during the first
year of life and demonstrated an astounding
78% reduced risk of type 1 diabetes over a
30-year follow-up [44]. A small placebo
controlled trial of vitamin D3 (4000 IU/day for
6 months) supplementation showed reduced
insulin resistance in a South Asian population
who were vitamin D deficient [45].
Recently, in an observational study of
patients in the 5-year Fenofibrate Intervention
and Event Lowering in Diabetes (FIELD) trial,
low blood 25(OH)D concentrations were
associated with an increased risk of
macrovascular and microvascular disease
events in type 2 diabetes [46]. A 25(OH)D
concentration \20 ng/mL had a higher
cumulative incidence of macrovascular and
microvascular events than those with levels
C20 ng/mL [46]. Indeed severe vitamin D
deficiency has been shown to predict not only
mortality but the development of nephropathy
and retinopathy in type 1 diabetes [47].
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VITAMIN D, NERVES,
AND DIABETIC NEUROPATHY
Previously studies of vitamin D have largely
focused on bone health and calcium
metabolism [1]; however, an increasing body
of evidence particularly over the past two
decades implicates a role of vitamin D in the
nervous system [48, 49]. Multiple
neurodegenerative diseases including multiple
sclerosis [50–54] and Parkinson’s disease [55], as
well as cognitive decline in the elderly [56],
have been linked with declining vitamin D
status. There are some data to suggest that
treatment with high doses of vitamin D3 slows
down the progression of disability linked to
multiple sclerosis [57]; however, further larger
interventional studies are required to truly
assess any therapeutic benefit [58].
Nerve growth factor (NGF) was first
identified as being essential for the
development of nociceptive primary neurons
and later found to have a role in inflammatory
hyperalgesia in adults [59]. NGF is a
neurotrophic factor which is synthesized
initially as pro-NGF, prior to being cleaved by
intracellular proteases before being translocated
to the rough endoplasmic reticulum and is
cleaved a second time by extracellular
proteases to produce the active form [59]. NGF
is responsible for the development and
maintenance of neurons in several regions in
the central nervous system [59, 60]. In addition,
following neuronal injury, NGF has the ability
to promote myelination of Schwann cells,
stimulate axonal sprouting, and guide axonal
growth [61]. 1,25(OH)2D3 has been shown to
cross the blood–brain barrier in experimental
models [62] and may act with relative specificity
to increase NGF in glial cells [63] and fibroblasts
[64]. Its receptors are found in the brain in
discrete regions [65]. In experimental studies,
vitamin D has been linked to the regulation of
neurotrophins such as NGF and neuronal Ca2?
homeostasis, both of which may play a
neuroprotective role in the peripheral nerve
[66]. Riaz et al. [66] showed that sciatic nerve
NGF was preserved in animals exposed to a
vitamin D analogue (CB1093) whilst another
vitamin D analogue (MC903) has been shown
to increase NGF synthesis [67]. NGF is known to
be depleted in experimental diabetes [68] and in
a study of patients with diabetic neuropathy a
significant correlation was demonstrated
between skin keratinocyte NGF
immunostaining and skin axon-reflex
vasodilation, mediated by small sensory fibers
[69]. Stimulation of neurotrophin production
by 1,25(OH)2D3 is correlated with a
neuroprotective effect [66, 70] and other than
NGF, glial cell line-derived neurotrophic factor
(GDNF) is also upregulated by 1,25(OH)2D3
[71]. It is notable that in central nervous
system tumors, 1,25(OH)2D3 and several
synthetic analogues are effective in inducing a
cell death pathway in glioma cells [72–74]. Also
1,25-(OH)D3 regulates low affinity
neurotrophin receptors (p75) [75].
Importantly, topical application of NGF in
diabetic foot ulcers has resulted in promotion
of healing [76]. NGF has previously been
successfully studied in phase 2 clinical trials
[77] but showed a lack of efficacy in a phase 3
study for DPN [78].
The prevalence of DPN can be as high as
50% [79] and symptomatic diabetic
neuropathy can affect approximately 30% of
diabetic patients with neuropathy [80].
Currently there are no licensed therapies
which may alter the natural history of DPN;
therefore, symptom control remains the
mainstay of DPN management. Even for
symptom relief, effective treatment continues
to remain a major challenge and
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anticonvulsants and antidepressants are
first-line therapy with a 50% reduction in
pain considered a good outcome [81].
In the largest observational study to date of
diabetic patients in a primary care cohort in the
UK (n = 15,692), the prevalence of painful
symptoms and painful DPN was 34% and
21% in South Asians and Europeans,
respectively [82]. Additionally the adjusted risk
of painful neuropathic symptoms in type 2
diabetes was double that of type 1 diabetes (OR,
2.1; 95% CI, 1.7–2.4; P\0.001) and women had
a 50% increased adjusted risk of painful
symptoms compared with men (OR, 1.5; 95%
CI, 1.4–1.6; P\0.0001). Furthermore, despite a
lower prevalence of neuropathy in South Asians
(14%) compared to Europeans (22%) and
African Caribbeans (21%; P\0.0001), painful
symptoms were greatest in South Asians (38%
vs. 34% vs. 32%, P\0.0001). South Asians
without neuropathy maintained a 50%
increased risk of painful neuropathic
symptoms compared with other ethnic groups
(P\0.0001). These differences may partly be
explained in relation to vitamin D deficiency as
these groups have been shown to have excess
vitamin D deficiency [83]. Other studies have
assessed ethnic differences in DPN in a US
population with variations noted in risk for
DPN and diabetic autonomic neuropathy [84].
However, in an Australian study there were no
significant differences between ethnic groups
[85] although the ethnic mix of the last two
studies differs from that in the UK.
An increasing body of data suggests that
vitamin D may have not only analgesic
properties but also additional neuroprotective
benefits. Vitamin D deficiency and insufficiency
are associated with various pain syndromes and
low levels of vitamin D correlated with the
presence of peripheral neuropathy in primary
Sjo¨gren’s syndrome which can lead to a small
fiber neuropathy [86]. Vitamin D
supplementation has been shown to improve
musculoskeletal pain and non-traumatic back
pain in some studies [87]. However, there is a
prominent contrast in treatment effects
between randomized, double-blind trials that
minimized bias and those with designs known
to be subject to bias [87] with better treatment
effects noted in the latter. Therefore, the overall
evidence for the use of vitamin D for chronic
pain in adults is poor because of low-quality and
insufficient RCTs [87]. Pain thresholds of
multiple etiologies have been reported to be
lowered with vitamin D deficiency and elevated
when the vitamin D deficiency is corrected [88].
Previous observational studies have
demonstrated a significant link between
vitamin D deficiency and DPN [89–91]. In the
National Health and Nutrition Examination
Survey (NHANES) 2001–2004, an unweighted
sample of 591 subjects with diabetes
demonstrated a significant association between
vitamin D deficiency and both paresthesia (OR,
2.12; 95% CI, 1.17–3.85) and numbness (OR,
2.04; 95% CI, 1.18–3.52) after adjusting for
obesity, co-morbidities, use of medications for
neuropathy, diabetes duration, and glycemic
control [89]. Furthermore, in a prospective
observational study conducted by Skalli et al.
[91] in 111 consecutive ambulatory patients
with type 2 diabetes an association between
vitamin D deficiency and peripheral diabetic
neuropathy was found [91]. Although both
subjects with and without DPN were deficient,
those with DPN had approximately 4 ng/mL
lower 25(OH)D levels. In a further
cross-sectional study by Shehab et al. [90],
vitamin D deficiency was an independent risk
factor for DPN assessed using the neuropathy
symptom score and other clinical and
electrophysiological measures of DPN. The
duration of diabetes was higher in the group
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with peripheral neuropathy as was elevated
low-density lipoprotein-cholesterol (LDL). This
latter observation may be of relevance as both
vitamin D and cholesterol share a common
metabolic pathway through
7-dehydrocholestrol [3]. In a more recent
study conducted in a small homogenous
population in rural Turkey, reduced serum
25(OH)D was associated with DPN [92];
interestingly, neither VDR nor VDR-binding
protein differed between those with and
without DPN [92]. Large nerve fiber deficits
have also been associated with vitamin D status
in diabetes mellitus [93]. In an age, sex, body
mass index (BMI), height, and disease duration
matched cohort (n = 33) of patients with
diabetes, 25(OH)D was significantly lower in
the DPN group (21.2 ± 11.5 vs. 13.5 ± 5.1 ng/
mL, P = 0.001) [93]. After further adjustment for
all studied variables, serum vitamin D had an
independent and inverse association with both
DPN presence and severity, as each 1 ng/mL
increase in serum 25(OH)D was correlated with
2.2% and 3.4% decrease in the presence and
severity of nerve conduction studies (NCV)
impairment, respectively [93]. In a
meta-analysis of six studies that involved a
total of 1484 patients with type 2 diabetes,
vitamin D deficiency (\20 ng/mL) was
significantly associated with an increased risk
of DPN [94]. The OR was 2.88 (95% CI,
1.84–4.50; P\0.00001) with an adjusted OR of
2.68 (95% CI, 1.67–4.30; P\0.0001) in a
subanalysis of three studies [94], suggesting
that ‘‘vitamin D deficiency is very likely to be
associated with DPN in type 2 diabetic patients’’
[94]. Of course, hypertension itself is an
independent risk factor for DPN [95, 96] and
the interaction between vitamin D and the
RAAS may provide a further link.
To date clinical trials of vitamin D
intervention for DPN are limited. A single case
report has shown reversal of symptoms in severe
intractable painful diabetic neuropathy with
the administration of 50,000 IU ergocalciferol
(vitamin D2) weekly with almost complete
resolution by 4 weeks [97]. Despite the fact
that the patient was not severely deficient
with a baseline 25(OH)D of approximately
16 ng/mL, the subsequent pain relief from the
weekly ergocalciferol dose enabled the
discontinuation of oxycodone [97]. Lee et al.
[98] conducted an open-label uncontrolled
study in patients with vitamin D deficiency
and 51 patients with painful DPN. After
treatment with oral cholecalciferol (vitamin
D3) at a mean dose of 2059 IU daily for
3 months there was an improvement of
approximately 50% on the Visual Analogue
Scale (pain) [98]. Although the placebo effect
can be considerable in trials of therapeutic
agents in painful DPN, the maximal placebo
effect expected would be no more than
approximately 30% [99]. Indeed a 50% pain
reduction is considered to be efficacious when
evaluating interventions in painful DPN [99].
Valensi et al. [100] conducted a double-blind
RCT of a compound (QR-333) containing a
vitamin D analogue and showed positive effects
on numbness, jolting pain, and irritation in
subjects with painful DPN. However, the
outcomes of this study are somewhat
confounded as QR-333 contained quercetin, a
flavonoid with aldose reductase inhibitor
effects, which is one of the key pathogenetic
pathways causing diabetic neuropathy.
One of the key ‘hard endpoints’ of DPN is
foot ulceration, which may eventually lead to
lower limb amputation and significant
morbidity and mortality [101]. In a
cross-sectional study of diabetic patients
without (n = 162) and with (n = 162) plantar
ulcers, lower 25(OH)D status was associated
with plantar ulceration in patients with
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diabetes (6.3 vs. 28 ng/mL, P\0.005) [102]. In a
further study by Tiwari et al. [103], vitamin D
deficiency was more prevalent and severe in
patients with diabetic foot infection. Cases of
foot infection (n = 125) had a greater risk of
vitamin D deficiency (25(OH)D \20 ng/mL)
than controls (n = 164) with an OR of 1.8
(95% CI, 1.1–3.0; P = 0.02) and the risk of
severe vitamin D deficiency (25(OH)D\10 ng/
mL) was significantly higher in cases than in
controls with an OR of 4.0 (95% CI, 2.4–6.9;
P\0.0001) [103].
VITAMIN D AND DIABETIC
NEPHROPATHY
Considerable data exist on the role of vitamin D
in diabetic nephropathy [104]. Patients with
chronic kidney disease (CKD) are known to
have deficiency of both 25(OH)D and
1,25(OH)2D, which is associated with a high
cardiovascular mortality. These risks can be
partially ameliorated by treatment with vitamin
D analogues [105]. Although in patients with
CKD, higher levels of vitamin D may also be
associated with vascular calcification [106].
Experimental studies have shown a role of the
VDR, and VDR-mediated vitamin D actions are
thought to be renoprotective in diabetic
nephropathy [107]. In an experimental study,
vitamin D/VDR signaling in podocytes played a
critical role in the protection of the kidney from
diabetic injury [108]. Analysis of the NHAHES
(2001–2006) cross-sectional data showed that
there was an independent association between
vitamin D deficiency and insufficiency with the
presence of nephropathy [109]. In a small
double-blind, randomized placebo-controlled,
crossover trial of paracalcitriol (a vitamin D
analogue) in patients with proteinuria despite
adequate RAAS blockade, the urinary albumin
excretion rate was significantly further lowered
compared to placebo [110]. Furthermore,
combination therapy with an AT1 blocker and a
vitamin D analogue markedly ameliorated
diabetic nephropathy in an experimental
model of diabetic nephropathy [111]. In the
VITAL study (ClinicalTrials.gov identifier,
NCT00421733), a placebo-controlled,
double-blind RCT, paracalcitriol (a vitamin D
analogue) added to RAAS inhibition at a dose of
2 lg/day significantly lowered blood pressure
and residual albuminuria in patients with
diabetic nephropathy [112], further
highlighting the role of vitamin D as a potent
RAAS inhibitor [113, 114]. Recently, a systematic
reviewandmeta-analysis byDerakhshanianet al.
[115] suggested that despite a higher risk for
nephropathy in vitamin D-deficient patients
with diabetes, vitamin D supplementation did
not support causality in this association. A
pooled data of urinary albumin–creatinine ratio
levels in clinical trials (five trials, n = 219)
suggested no significant change following
vitamin D supplementation [115]. However,
these studies were small and heterogeneous and
the vitaminD replacement dose was small. Thus,
largerwell-designedRCTswith adequate vitamin
D supplementation in diabetic nephropathy are
required.
VITAMIN D AND DIABETIC
RETINOPATHY
25(OH)D concentrations are associated with
optic chiasm volume [116] and several studies
have found an association between vitamin D
deficiency and age-related macular
degeneration (AMD) [117, 118]. In a mouse
model of ischemic retinopathy, 1,25(OH)2D was
shown to inhibit neovascularization in retinal
tissue [119]. In a Turkish cohort of 66 subjects,
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Aksoy et al. [120] demonstrated an inverse
correlation between worsening diabetic
retinopathy and lower 1,25-dihydroxyvitamin
D3 (active vitamin D). In 50 diabetic patients
with early-stage diabetic retinopathy (DR) with
vitamin D deficiency and 50 early-stage DR
without vitamin D deficiency, vitamin D
deficiency was associated with early retinal
nerve fibre layer (RNFL) thinning [121].
Furthermore, in a Korean study sampling
18,363 from the NHANES (2008–2012),
25(OH)D was associated with diabetic
retinopathy [122]. Similar results have been
replicated in a Chinese population with type 2
diabetes [123] and a Japanese population with
type 1 diabetes [124]. However, in the third
NHANES, no relationship was found between
25(OH)D levels and retinopathy severity [125].
Also the EURODIAB prospective complications
study showed no significant relationship
between 25(OH)D and retinopathy, despite a
positive relationship with microalbuminuria
[126]. Indeed, most recently, Alam et al. [127]
have shown no association between serum
25(OH)D concentrations and the presence and
severity of diabetic retinopathy or
maculopathy; however, the marked deficiency
in their population may have confounded the
study as approximately 91% of subjects were
deficient/insufficient (25(OH)D \30 ng/mL)
[127]. Thus further studies are required to
elucidate the relationship between vitamin D
and DR.
CONCLUSIONS
The prevalence of vitamin D deficiency is in
pandemic proportions in the UK and
worldwide, particularly in the diabetic
population. An increasing body of literature
suggests a possible pathogenetic role of
vitamin D in the long-term complications of
diabetes and vitamin D deficiency may also
exacerbate symptoms of painful DPN. Despite
a number of well-designed observational
studies a causal link remains to be
demonstrated. The association between
vitamin D status and cardiometabolic
outcomes is uncertain, especially as
intervention trials have shown no clinically
significant effect of vitamin D
supplementation. However, short-term
underpowered interventions with low doses
of vitamin D may have produced limited
benefits. Given the widespread propensity to
deficiency and its low side effect profile,
vitamin D therapy represents a promising
therapeutic intervention in the treatment of
diabetic complications. In particular, there is
a significant need for good quality RCTs
using therapeutic doses (approximately
4000 IU/day) of vitamin D in painful DPN.
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